STANDARD BIOTOOLS INC.
Standard BioTools Inc. (NASDAQ: SDTB) is a life sciences tools company committed to advancing biomedical research through strategic consolidation and best-in-class operations. The company operates through continuing operations focused on proteomics and genomics platforms following the sale of its SomaScan Business to… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What STANDARD BIOTOOLS INC. does
In the company’s own words
Standard BioTools Inc. (NASDAQ: SDTB) is a life sciences tools company committed to advancing biomedical research through strategic consolidation and best-in-class operations. The company operates through continuing operations focused on proteomics and genomics platforms following the sale of its SomaScan Business to Illumina in January 2026.
The company's core portfolio includes three primary technology platforms. CyTOF leverages mass cytometry to detect and quantify over 50 intracellular and extracellular markers simultaneously, enabling high-dimensional immune profiling and biomarker discovery. Hyperion provides spatial biology capabilities through Imaging Mass Cytometry, allowing researchers to map multiple protein markers across tissue landscapes while preserving spatial context. Biomark X9 delivers high-throughput genomics through advanced microfluidics technology for qPCR applications, enabling simultaneous analysis of thousands of reactions in single runs.
Standard BioTools sells instruments and consumables for research use only to leading academic research institutions, translational research centers, cancer centers, clinical research laboratories, and biopharmaceutical and biotechnology companies. The company maintains direct sales forces and support organizations in North America, Europe, and Asia-Pacific, supplemented by distributors in additional regions. Manufacturing operations are located in Singapore and Canada, with the Singapore facility producing Integrated Fluidic Circuits and microfluidics instruments, while the Markham, Canada facility manufactures mass cytometry instruments, reagents, and genomics products.
As of December 31, 2025, the company employed 389 people worldwide, with 96 located in the United States. International revenue represented 67 percent of total revenue in 2025. The company owns or licenses approximately 400 patents with roughly 150 pending patent applications worldwide, with utility and design patents expiring through 2047. Standard BioTools maintains proprietary microfluidics technology developed from core genomics technology licensed from Caltech, Harvard University, and other institutions.
The company participates in a life sciences research tools market estimated at over 70 billion dollars annually, with particular focus on emerging proteomics and genomics segments. Standard BioTools also pursues original equipment manufacturer opportunities leveraging its proprietary microfluidics technology. The company's website is www.standardbiotools.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1162194
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns STANDARD BIOTOOLS INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · STANDARD BIOTOOLS INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do STANDARD BIOTOOLS INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of STANDARD BIOTOOLS INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in STANDARD BIOTOOLS INC.'s last four quarterly filings that the numbers alone won't show?”